Quanterix (NASDAQ:QTRX – Get Free Report) and Danaher (NYSE:DHR – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.
Profitability
This table compares Quanterix and Danaher’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quanterix | -75.05% | -30.49% | -22.44% |
| Danaher | 16.91% | 11.17% | 6.71% |
Institutional & Insider Ownership
86.5% of Quanterix shares are held by institutional investors. Comparatively, 79.0% of Danaher shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 10.8% of Danaher shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Quanterix has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Danaher has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.
Valuation & Earnings
This table compares Quanterix and Danaher”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quanterix | $138.90 million | 0.97 | -$107.15 million | ($2.36) | -1.20 |
| Danaher | $24.57 billion | 6.59 | $3.61 billion | $6.11 | 37.64 |
Danaher has higher revenue and earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Quanterix and Danaher, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quanterix | 1 | 2 | 0 | 0 | 1.67 |
| Danaher | 0 | 5 | 18 | 0 | 2.78 |
Quanterix presently has a consensus price target of $3.50, suggesting a potential upside of 23.24%. Danaher has a consensus price target of $242.91, suggesting a potential upside of 5.61%. Given Quanterix’s higher possible upside, research analysts plainly believe Quanterix is more favorable than Danaher.
Summary
Danaher beats Quanterix on 10 of the 13 factors compared between the two stocks.
About Quanterix
Quanterix Corporation develops technologies for measuring biomarkers in biological samples. Its Simoa (Single Molecule Array) platform is designed to detect proteins and other biomarkers at very low concentrations, supporting research in areas such as neurology, oncology, immunology and cardiovascular disease. The company provides laboratory instruments, assay kits, consumables and related services. Its products are used by pharmaceutical and biotechnology companies, academic institutions and laboratories to study disease biology and evaluate potential biomarkers in samples such as blood and cerebrospinal fluid.
About Danaher
Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.
